Loading clinical trials...
Loading clinical trials...
Caelyx(R) in Breast Cancer in the Elderly. Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer.
Conditions
Interventions
Caelyx (pegylated liposomal doxorubicin; SCH 200746)
Start Date
February 7, 2007
Primary Completion Date
October 16, 2009
Completion Date
October 16, 2009
Last Updated
June 7, 2017
NCT07191730
NCT06312176
NCT06797635
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions